From MarketBeat:

Becton, Dickinson and Company (NYSE:BDX) saw a significant drop in short interest in December, from 2,620,000 shares to 2,430,000 shares. This represents about 0.8% of the shares being sold short, with a short-interest ratio of 1.6 days.

Several analysts weighed in on Becton, Dickinson and Company, with mixed opinions. Some reduced price targets, while others increased price targets and rating the company a “buy” or “hold.”

On Wednesday, Becton, Dickinson and Company stock dropped 2.1%, trading at $240.32. The company has a market capitalization of $69.79 billion and a PE ratio of 48.45. The stock also saw a decrease in price targets from analysts.

Becton, Dickinson and Company reported a quarterly dividend and experienced insider activity. EVP Richard Byrd sold over 2,000 shares in November, and corporate insiders own 0.31% of the company’s stock.

Institutional investors have been making significant changes to their positions in the stock, with some increasing their stakes.

Overall, despite analysts’ varying opinions, Becton, Dickinson and Company still holds a “Moderate Buy” rating, with an average price target of $280.43.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.



Read more: Becton, Dickinson and Company (NYSE:BDX) Short Interest Update